The Effect of Teriparatide on the Hip: A Literature Review

키워드

참고문헌 (61)

1. Shoback D, "Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update", J Clin Endocrinol Metab, 105, pp.dgaa048~ (2020)
2. Lloyd R, "Co-morbidities in patients with a hip fracture", Ulster Med J, 88, pp.162~166 (2019)
3. Langdahl BL, "Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide : 18-month data from the European Forsteo Observational Study(EFOS)", Calcif Tissue Int, 85, pp.484~493 (2009)
4. Graeff C, "Monitoring teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo : results from the EUROFORS study", J Bone Miner Res, 22, pp.1426~1433 (2007)
5. Schnell R, "Changes in cross-sectional area of spinal canal and vertebral body under 2 years of teriparatide treatment : results from the EUROFORS study", Calcif Tissue Int, 87, pp.130~136 (2010)
6. Neer RM, "Effect of parathyroid hormone(1-34)on fractures and bone mineral density in postmenopausal women with osteoporosis", N Engl J Med, 344, pp.1434~1441 (2001)
7. Holzer G, "Hip fractures and the contribution of cortical versus trabecular bone to femoral neck strength", J Bone Miner Res, 24, pp.468~474 (2009)
8. Pazianas M, "Anabolic effects of PTH and the ‘anabolic window’", Trends Endocrinol Metab, 26, pp.111~113 (2015)
9. Leder BZ, "Two years of Denosumab and Teriparatide Administration in postmenopausal women with osteoporosis(the DATA extension study) : a randomized controlled trial", J Clin Endocrinol Metab, 99, pp.1694~1700 (2014)
10. Dempster DW, "Remodeling-and modeling-based bone formation with teriparatide versus denosumab : a longitudinal analysis from baseline to 3 months in the AVA study", J Bone Miner Res, 33, pp.298~306 (2018)
11. Lindsay R, "A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy : early actions of teriparatide", J Bone Miner Res, 21, pp.366~373 (2006)
12. McClung MR, "Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass", Arch Intern Med, 165, pp.1762~1768 (2005)
13. Prince R, "Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment", J Bone Miner Res, 20, pp.1507~1513 (2005)
14. treatment in postmenopausal women with osteoporosis, "Osteoporos Int", 2008, 87~94
15. Boonen S, "Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis", J Clin Endocrinol Metab, 93, pp.852~860 (2008)
16. Cosman F, "Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene : differences between stopping and continuing the antiresorptive agent", J Clin Endocrinol Metab, 94, pp.3772~3780 (2009)
17. Tsai JN, "Effects of teriparatide, denosumab, or both on spine trabecular microarchitecture in DATA-switch : a randomized controlled trial", J Clin Densitom, 20, pp.507~512 (2017)
18. Black DM, "Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction : meta-regression analyses of individual patient data from multiple randomised controlled trials", Lancet Diabetes Endocrinol, 8, pp.672~682 (2020)
19. Díez-Pérez A, "Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis : a systematic review and meta-analysis", Bone, 120, pp.1~8 (2019)
20. Silverman S, "Reduction of hip and other fractures in patients receiving teriparatide in realworld clinical practice : integrated analysis of four prospective observational studies", Calcif Tissue Int, 104, pp.193~200 (2019)
21. Silverman S, "The Direct Assessment of Nonvertebral Fractures in Community Experience(DANCE)study : 2-year nonvertebral fragility fracture results", Osteoporos Int, 24, pp.2309~2317 (2013)
22. Langdahl BL, "Fracture rate, quality of life and back pain in patients with osteoporosis treated with teriparatide : 24-month results from the Extended Forsteo Observational Study(ExFOS)", Calcif Tissue Int, 99, pp.259~271 (2016)
23. Soen S, "Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture : final results from the 24-month Japan Fracture Observational Study(JFOS)", Curr Med Res Opin, 33, pp.2049~2056 (2017)
24. Turner CH, "Biomechanics of bone : determinants of skeletal fragility and bone quality", Osteoporos Int, 13, pp.97~104 (2002)
25. Seeman E, "Periosteal bone formation--a neglected determinant of bone strength", N Engl J Med, 349, pp.320~323 (2003)
26. Burr DB, "Intermittently administered human parathyroid hormone(1-34)treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys", J Bone Miner Res, 16, pp.157~165 (2001)
27. Ma YL, "Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis", J Bone Miner Res, 21, pp.855~864 (2006)
28. Eriksen EF, "Teriparatide : a bone formation treatment for osteoporosis", Drugs Today(Barc), 40, pp.935~948 (2004)
29. Ma YL, "Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment", Bone, 59, pp.139~147 (2014)
30. Kanis JA, "Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds", Osteoporos Int, 12, pp.989~995 (2001)
31. Silva BC, "Catabolic and anabolic actions of parathyroid hormone on the skeleton", J Endocrinol Invest, 34, pp.801~810 (2011)
32. Makras P, "Bone disease in primary hyperparathyroidism", Metabolism, 80, pp.57~65 (2018)
33. Dempster DW, "Anabolic actions of parathyroid hormone on bone", Endocr Rev, 14, pp.690~709 (1993)
34. Neer M, "Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol", Osteoporos Int, 3(Suppl 1), pp.204~205 (1993)
35. strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity, "J Bone Miner Res", 2004, 623~629
36. Hansen S, "Differing effects of PTH 1-34, PTH 1-84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis : an 18-month open-labeled observational study using HR-pQCT", J Bone Miner Res, 28, pp.736~745 (2013)
37. Osima M, "Serum parathyroid hormone is associated with increased cortical porosity of the inner transitional zone at the proximal femur in postmenopausal women : the Tromsø study", Osteoporos Int, 29, pp.421~431 (2018)
38. Ellegaard M, "Parathyroid hormone and bone healing", Calcif Tissue Int, 87, pp.1~13 (2010)
39. Manabe T, "Human parathyroid hormone(1-34)accelerates natural fracture healing process in the femoral osteotomy model of cynomolgus monkeys", Bone, 40, pp.1475~1482 (2007)
40. Resmini G, "79-year-old post-menopausal woman with humerus fracture during teriparatide treatment", Aging Clin Exp Res, 19(4 Suppl), pp.30~31 (2007)
41. Yu CT, "Early callus formation in human hip fracture treated with internal fixation and teriparatide", J Rheumatol, 35, pp.2082~2083 (2008)
42. Raghavan P, "Role of teriparatide in accelerating metatarsal stress fracture healing : a case series and review of literature", Clin Med Insights Endocrinol Diabetes, 5, pp.39~45 (2012)
43. Lee YK, "Teriparatide, a nonsurgical solution for femoral nonunion? A report of three cases", Osteoporos Int, 23, pp.2897~2900 (2012)
44. Aspenberg P, "Teriparatide for acceleration of fracture repair in humans : a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures", J Bone Miner Res, 25, pp.404~414 (2010)
45. Iwamoto N, "A comparison of the effects of alendronate and alfacalcidol on bone mineral density around the femoral implant and in the lumbar spine after total hip arthroplasty", J Bone Joint Surg Am, 93, pp.1203~1209 (2011)
46. Bloebaum RD, "Relationship between bone ingrowth, mineral apposition rate, and osteoblast activity", J Biomed Mater Res A, 81, pp.505~514 (2007)
47. Zeng Y, "A systematic review assessing the effectiveness of alendronate in reducing periprosthetic bone loss after cementless primary THA", Orthopedics, 34, pp.261~ (2011)
48. Tapaninen TS, "Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty-a 5-year followup of 16 patients", Scand J Surg, 99, pp.32~37 (2010)
49. Kobayashi N, "Teriparatide versus alendronate for the preservation of bone mineral density after total hip arthroplasty-a randomized controlled trial", J Arthroplasty, 31, pp.333~338 (2016)
50. Shane E, "Atypical subtrochanteric and diaphyseal femoral fractures : second report of a task force of the American Society for Bone and Mineral Research", J Bone Miner Res, 29, pp.1~23 (2014)
51. Toro G, "Management of atypical femoral fracture : a scoping review and comprehensive algorithm", BMC Musculoskelet Disord, 17, pp.227~ (2016)
52. Schilcher J, "Bisphosphonate use and atypical fractures of the femoral shaft", N Engl J Med, 364, pp.1728~1737 (2011)
53. Park-Wyllie LY, "Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women", JAMA, 305, pp.783~789 (2011)
54. Gomberg SJ, "Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy", J Clin Endocrinol Metab, 96, pp.1627~1632 (2011)
55. Mastaglia SR, "Teriparatide for the rapid resolution of delayed healing of atypical fractures associated with long-term bisphosphonate use", Eur J Rheumatol, 3, pp.87~90 (2016)
56. Huang HT, "Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman : a case report", Menopause, 19, pp.1360~1363 (2012)
57. Shin WC, "A retrospective bicenter comparative study of surgical outcomes of atypical femoral fracture : potential effect of teriparatide on fracture healing and callus formation", Bone, 128, pp.115033~ (2019)
58. Yeh WL, "Surgical outcome of atypical subtrochanteric and femoral fracture related to bisphos phonates use in osteoporotic patients with or without teriparatide treatment", BMC Musculoskelet Disord, 18, pp.527~ (2017)
59. Miyakoshi N, "Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis : a comparison between treatment with and without teriparatide", J Bone Miner Metab, 33, pp.553~559 (2015)
60. Watts NB, "Responses to treatment with teriparatide in patients with atypical femur fractures previously treated with bisphosphonates", J Bone Miner Res, 32, pp.1027~1033 (2017)
61. Greenspan SL, "Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur", Osteoporos Int, 29, pp.501~506 (2018)

관련 논문AI추천